Cyclin G2: A novel independent prognostic marker in pancreatic cancer

Shinichiro Hasegawa, Hiroaki Nagano, Masamitsu Konno, Hidetoshi Eguchi, Akira Tomokuni, Yoshito Tomimaru, Hiroshi Wada, Naoki Hama, Koichi Kawamoto, Shogo Kobayashi, Shigeru Marubashi, Naohiro Nishida, Jun Koseki, Noriko Gotoh, Shouichi Ohno, Norikazu Yabuta, Hiroshi Nojima, Masaki Mori, Yuichiro Doki, Hideshi Ishii

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

Original languageEnglish
Pages (from-to)2986-2990
Number of pages5
JournalOncology Letters
Volume10
Issue number5
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Cyclin G2
Pancreatic Neoplasms
Neoplasms
Cyclins
Kaplan-Meier Estimate
Tumor Suppressor Genes
Cell Cycle
Multivariate Analysis
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hasegawa, S., Nagano, H., Konno, M., Eguchi, H., Tomokuni, A., Tomimaru, Y., ... Ishii, H. (2015). Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Oncology Letters, 10(5), 2986-2990. https://doi.org/10.3892/ol.2015.3667

Cyclin G2 : A novel independent prognostic marker in pancreatic cancer. / Hasegawa, Shinichiro; Nagano, Hiroaki; Konno, Masamitsu; Eguchi, Hidetoshi; Tomokuni, Akira; Tomimaru, Yoshito; Wada, Hiroshi; Hama, Naoki; Kawamoto, Koichi; Kobayashi, Shogo; Marubashi, Shigeru; Nishida, Naohiro; Koseki, Jun; Gotoh, Noriko; Ohno, Shouichi; Yabuta, Norikazu; Nojima, Hiroshi; Mori, Masaki; Doki, Yuichiro; Ishii, Hideshi.

In: Oncology Letters, Vol. 10, No. 5, 01.11.2015, p. 2986-2990.

Research output: Contribution to journalArticle

Hasegawa, S, Nagano, H, Konno, M, Eguchi, H, Tomokuni, A, Tomimaru, Y, Wada, H, Hama, N, Kawamoto, K, Kobayashi, S, Marubashi, S, Nishida, N, Koseki, J, Gotoh, N, Ohno, S, Yabuta, N, Nojima, H, Mori, M, Doki, Y & Ishii, H 2015, 'Cyclin G2: A novel independent prognostic marker in pancreatic cancer', Oncology Letters, vol. 10, no. 5, pp. 2986-2990. https://doi.org/10.3892/ol.2015.3667
Hasegawa S, Nagano H, Konno M, Eguchi H, Tomokuni A, Tomimaru Y et al. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Oncology Letters. 2015 Nov 1;10(5):2986-2990. https://doi.org/10.3892/ol.2015.3667
Hasegawa, Shinichiro ; Nagano, Hiroaki ; Konno, Masamitsu ; Eguchi, Hidetoshi ; Tomokuni, Akira ; Tomimaru, Yoshito ; Wada, Hiroshi ; Hama, Naoki ; Kawamoto, Koichi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Nishida, Naohiro ; Koseki, Jun ; Gotoh, Noriko ; Ohno, Shouichi ; Yabuta, Norikazu ; Nojima, Hiroshi ; Mori, Masaki ; Doki, Yuichiro ; Ishii, Hideshi. / Cyclin G2 : A novel independent prognostic marker in pancreatic cancer. In: Oncology Letters. 2015 ; Vol. 10, No. 5. pp. 2986-2990.
@article{39d598d131a3425bb5ce852e2ab1a499,
title = "Cyclin G2: A novel independent prognostic marker in pancreatic cancer",
abstract = "Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.",
author = "Shinichiro Hasegawa and Hiroaki Nagano and Masamitsu Konno and Hidetoshi Eguchi and Akira Tomokuni and Yoshito Tomimaru and Hiroshi Wada and Naoki Hama and Koichi Kawamoto and Shogo Kobayashi and Shigeru Marubashi and Naohiro Nishida and Jun Koseki and Noriko Gotoh and Shouichi Ohno and Norikazu Yabuta and Hiroshi Nojima and Masaki Mori and Yuichiro Doki and Hideshi Ishii",
year = "2015",
month = "11",
day = "1",
doi = "10.3892/ol.2015.3667",
language = "English",
volume = "10",
pages = "2986--2990",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Cyclin G2

T2 - A novel independent prognostic marker in pancreatic cancer

AU - Hasegawa, Shinichiro

AU - Nagano, Hiroaki

AU - Konno, Masamitsu

AU - Eguchi, Hidetoshi

AU - Tomokuni, Akira

AU - Tomimaru, Yoshito

AU - Wada, Hiroshi

AU - Hama, Naoki

AU - Kawamoto, Koichi

AU - Kobayashi, Shogo

AU - Marubashi, Shigeru

AU - Nishida, Naohiro

AU - Koseki, Jun

AU - Gotoh, Noriko

AU - Ohno, Shouichi

AU - Yabuta, Norikazu

AU - Nojima, Hiroshi

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Ishii, Hideshi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

AB - Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84942475354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942475354&partnerID=8YFLogxK

U2 - 10.3892/ol.2015.3667

DO - 10.3892/ol.2015.3667

M3 - Article

AN - SCOPUS:84942475354

VL - 10

SP - 2986

EP - 2990

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -